IM Cannabis Corp. Announces Board Restructuring and New Business Strategy Exploration

IM Cannabis Corp. Restructures Board and Seeks New Opportunities

IM Cannabis Corp. (Nasdaq: IMCC), a prominent player in the medical cannabis industry with significant operations in both Israel and Germany, has recently made headlines with crucial changes to its board of directors. On September 15, 2025, the company announced the resignation of two board members, Shmulik Arbel and Brian Schinderle, from their respective positions on the Board, Audit Committee, and Compensation Committee.

In response to these vacancies, the company has swiftly appointed Asaf Yitzhaik and Eli Zamir as new members of the Board, effective immediately. Both appointees bring a wealth of experience and expertise that is anticipated to bolster IMC's strategic direction. Yitzhaik, a seasoned businessman with an impressive three-decade career in retail and real estate, is known for owning ASI Glasses, a well-established company in the optics sector in Israel. His extensive background in managing numerous publicly traded companies also adds to his credentials.

Eli Zamir complements the board with his deep knowledge of finance and public company governance. His past roles include CEO of an underwriting firm and CFO of a public real estate company. Zamir's expertise in capital markets will be indispensable as the company looks to expand its business operations. Currently, he leads Jeff's Brands Ltd. while also advising on mergers and financing initiatives in the renewable energy sector across Europe.

Oz Adler, another director in the company, has been appointed as the new Chairman of the Board, replacing Oren Shuster, who will continue in his roles as Chief Executive Officer and board member. Shuster expressed gratitude to the departing members for their contributions and warmly welcomed the new members to the team, emphasizing the company’s enthusiasm to leverage their expertise to advance IMC's strategic goals.

Additionally, the company has embarked on a strategic review aimed at identifying new business opportunities to foster long-term growth and enhance shareholder value. This exploration underscores IM Cannabis's commitment to sustainability and profitability in the increasingly competitive landscape of the global cannabis market.

IM Cannabis is resolute in its mission to provide premium cannabis products to medical patients in key markets such as Israel and Germany. The company operates through a transnational ecosystem that benefits from a unique data-driven approach and a globally sourced supply chain. This strategy not only positions IMC favorably within the industry but also reflects its commitment to complying with stringent regulatory environments.

As part of its operations, IM Cannabis manages the importation and distribution of cannabis products to medical end-users, while also providing retail services through pharmacies and online platforms to ensure a seamless delivery process. The company’s facility in Germany, Adjupharm GmbH, plays a pivotal role in distributing cannabis to pharmacies, further solidifying its presence in the European market, which is seeing the legalization of cannabis for medical purposes.

Overall, the recent board restructuring and strategic initiative represent a pivotal moment for IM Cannabis Corp. as it seeks to drive forward with its growth agenda, ensuring that it remains a top contender in the international cannabis market. The leadership changes and fresh strategy signal optimism for both the company and its stakeholders as they navigate the evolving landscape of the cannabis industry, which continues to offer substantial opportunities for innovation and expansion.

Disclaimer: This article may contain forward-looking statements which involve inherent risks and uncertainties. Actual outcomes may differ materially due to various factors. Please conduct your own research before making any investment decisions.